AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ImpediMed Announces PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons

March 25, 2019

CARLSBAD, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Mar 25, 2019--ImpediMed Limited (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announces that the pre-specified, interim detailed results of the PREVENT trial will be presented during the scientific session of the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) in Dallas, Texas, April 30 – May 5, 2019.

ASBrS is the primary leadership organization for general surgeons who treat patients with breast disease and is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. The results of the PREVENT trial are subject to the embargo policy of the ASBrS 20th Annual Meeting. All scientific abstracts accepted for oral or poster presentation during the Society’s 20th Annual Meeting, press releases, and the Society’s Official Proceedings are embargoed until 12:30 pm Eastern time, May 2, 2019.

The full PREVENT manuscript has been accepted for publication by the Annals of Surgical Oncology and will be released immediately following the presentation by the PREVENT trial principal investigator Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing. The Annals of Surgical Oncology is one of the leading journals in oncology and surgery and features original articles on the latest advances in oncology for surgeons from all specialties.

Richard Carreon, managing director and CEO, ImpediMed says, “We’re pleased and honored that the groundbreaking trial results were selected by the ASBrS for podium presentation during the scientific session at the upcoming annual meeting. PREVENT is a landmark study, the most rigorously conducted trial for evaluating the impact of BIS on detecting, monitoring and treating cancer-related lymphedema. The opportunity to highlight the results of the PREVENT trial at the prestigious ASBrS meeting exemplifies our commitment to improve the quality of care for millions of cancer survivors suffering from lymphedema worldwide. We look forward to partnering with our medical advisors to enhance awareness for the detection, monitoring and prevention of this devastating condition.”

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO ® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

About the PREVENT Study

The PREVENT trial, A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement in the Prevention of Lymphedemafollowing Locoregional Treatment for Breast Cancer, is an international, multi-institutional, randomized controlled trial designed to follow 1100 patients for three years at 10 medical centers across the US and Australia. Patients are randomized to follow up using L-Dex or volume measurements (circumference) using tape measure. The trial is being conducted by some of the most prestigious cancer centers including Vanderbilt University, Macquarie University, MD Anderson Cancer Center, Mayo Clinic, University of Kansas Cancer Center and Columbia University.

About BIS

Bioimpedance spectroscopy (BIS) differs fundamentally from other bioimpedance approaches. ImpediMed’s BIS devices measure impedance at 256 different frequencies over a full spectrum from 3 kHz to 1000 kHz and do not depend upon population-specific prediction equations to generate fluid volumes or tissue masses. ImpediMed’s BIS technology does not assume that extracellular fluid (ECF) and intracellular fluid (ICF) are uniformly distributed. Therefore, this technique provides a more direct and individualized measure of ECF, ICF, and total body water (TBW) compartments of the body compared with other approaches. This has significant advantages, particularly in patient populations with altered fluid homeostasis.

About the ASBrS Embargo Policy

All scientific abstracts accepted for oral or poster presentation during the Society’s 20th Annual Meeting, press releases, and the Society’s Official Proceedings are embargoed until 12:30 pm Eastern time, May 2, 2019. The Society strictly enforces its embargo policy, which prohibits the distribution or publication of the contents of abstracts ahead of the embargo time. Embargoed press releases and official proceedings of the meeting will be distributed to registered credentialed press in advance of the meeting. Failure to abide by the Society’s embargo policy will result in forfeiture of press credentials for this and future annual meetings.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005064/en/

CONTACT: Media:

Laura Carabello

lcarabello@cpronline.com

201.641.1911 x12

KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA TEXAS

INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY RESEARCH FDA SCIENCE

SOURCE: ImpediMed Limited

Copyright Business Wire 2019.

PUB: 03/25/2019 09:00 AM/DISC: 03/25/2019 09:00 AM

http://www.businesswire.com/news/home/20190325005064/en